Trials / Completed
CompletedNCT01224366
Efficacy and Safety of Vildagliptin as add-on Therapy to Insulin in Patients With Type 2 Diabetes Mellitus
A 24-week, Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Assess the Efficacy and Safety of Vildagliptin 50mg Bid as an add-on Therapy to Insulin, With or Without Metformin, in Patients With Type 2 Diabetes Mellitus.
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 448 (actual)
- Sponsor
- Novartis · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
To assess the efficacy and safety of vildagliptin add-on therapy to reduce HbA1c in patients with T2DM inadequately controlled by insulin, with or without concurrent metformin therapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Vildagliptin | |
| DRUG | Placebo |
Timeline
- Start date
- 2010-09-01
- Primary completion
- 2011-10-01
- Completion
- 2011-10-01
- First posted
- 2010-10-20
- Last updated
- 2017-02-23
Locations
66 sites across 11 countries: Australia, Belgium, Czechia, Germany, Guatemala, Hong Kong, Hungary, India, Romania, Slovakia, United Kingdom
Source: ClinicalTrials.gov record NCT01224366. Inclusion in this directory is not an endorsement.